

February 9, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir / Madam,

Sub: Unaudited Financial Results for the quarter and nine months period ended December 31, 2025

The Board of Directors of the Company at its meeting held today, February 9, 2026, has, inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors.

The Board meeting commenced at 4:30 p.m. and concluded at 6:30 p.m.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihiar, Ameerpet, Hyderabad-500 038, Telangana, India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

AUROBINDO PHARMA LIMITED
 (CIN - L24239TG1986PLC015190)
www.aurobindo.com

Regd. Office: Plot No.2, Maitrivan, Ameerpet, Hyderabad - 500 038, India
 Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ million, unless otherwise stated)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025						
	Particulars	Quarter ended		Nine months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations					
	(a) Net sales/ income from operations	27,263.8	27,598.9	28,835.6	83,084.1	80,666.6
	(b) Other operating income	209.0	298.3	330.7	767.6	1,346.5
	Total revenue from operations	27,472.8	27,897.2	29,166.3	83,851.7	82,013.1
2	Other income					
	(a) Foreign exchange gain (net)	589.7	591.5	-	1,587.2	679.7
	(b) Others	711.8	1,003.7	542.6	2,147.2	1,461.7
	Total other income	1,301.5	1,595.2	542.6	3,734.4	2,141.4
3	Total income (1+2)	28,774.3	29,492.4	29,708.9	87,586.1	84,154.5
4	Expenses					
	(a) Cost of materials consumed	14,025.5	12,441.6	15,065.9	39,867.2	42,495.1
	(b) Purchase of stock-in-trade	201.5	221.5	190.6	566.8	488.2
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1,359.9)	1,012.7	(613.7)	37.6	(1,281.8)
	(d) Employee benefits expense	2,911.0	2,943.7	2,651.5	8,684.4	7,899.6
	(e) Finance costs	484.3	574.5	661.9	1,658.8	1,689.5
	(f) Foreign exchange loss (net)	-	-	281.0	-	-
	(g) Depreciation and amortisation expenses	719.2	714.9	682.8	2,134.3	2,033.2
	(h) Other expenses	3,799.9	4,030.7	4,459.5	11,590.5	12,801.4
	Total expenses	20,781.5	21,939.6	23,379.5	64,539.6	66,125.2
5	Profit before exceptional items and tax (3-4)	7,992.8	7,552.8	6,329.4	23,046.5	18,029.3
6	Exceptional items (refer note 4)	173.8	-	-	173.8	-
7	Profit before tax (5-6)	7,819.0	7,552.8	6,329.4	22,872.7	18,029.3
8	Tax expense					
	Current tax	2,029.7	1,742.2	1,640.3	5,648.7	4,721.2
	Deferred tax	(31.4)	(3.1)	(31.4)	(1.7)	(78.1)
	Total tax expense	1,998.3	1,739.1	1,608.9	5,647.0	4,643.1
9	Profit after tax (7-8)	5,820.7	5,813.7	4,720.5	17,225.7	13,386.2
10	Other comprehensive income					
	Items that will not be reclassified subsequently to profit or loss:					
	(a) Re-measurement of defined benefit liability	(15.9)	(0.4)	(19.4)	(33.9)	(58.2)
	(b) Income-tax relating to items that will not be reclassified to profit or loss	4.0	0.1	4.9	8.5	14.7
	Total other comprehensive loss (net of tax)	(11.9)	(0.3)	(14.5)	(25.4)	(43.5)
11	Total comprehensive income (9+10)	5,808.8	5,813.4	4,706.0	17,200.3	13,342.7
12	Paid-up equity share capital (face value ₹ 1 per share)	580.8	580.8	580.8	580.8	580.8
13	Other equity					
14	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)
	(a) Basic (in ₹)	10.02	10.01	8.13	29.66	22.94
	(b) Diluted (in ₹)	10.02	10.01	8.13	29.66	22.94
						2,04,760.3 (Annualised)
						29.97 29.97



NOTES:

- 1 The above unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above unaudited standalone financial results of the Company as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on February 9, 2026. The results for the quarter and nine months ended December 31, 2025 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2025.
- 3 The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
- 4 On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability (arising out of past service cost) and increase in leave liability aggregating ₹ 173.8 million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount under "Exceptional Items" in the Standalone Statement of Profit and Loss for the quarter and nine months ended December 31, 2025. The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits.

By Order of the Board
For Aurobindo Pharma Limited



K. Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

Place: Hyderabad
Date : February 9, 2026



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **AUROBINDO PHARMA LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



C Manish Muralidhar
(Partner)
(Membership No. 213649)
(UDIN: 26213649OBZTAO4565)

Place: Hyderabad
Date: February 09, 2026

(All amounts are in ₹ million, unless otherwise stated)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations						
	(a) Net sales/ income from operations	86,045.1	82,369.6	78,931.5	2,46,332.4	2,29,970.1	3,13,781.3
	(b) Other operating income	413.9	487.4	853.7	1,665.0	3,446.0	3,456.0
	Total revenue from operations	86,459.0	82,857.0	79,785.2	2,47,997.4	2,33,416.1	3,17,237.3
2	Other income						
	(a) Foreign exchange gain (net)	335.0	49.8	-	380.9	-	-
	(b) Others	1,541.4	1,156.1	1,572.9	3,750.5	4,986.4	6,218.5
	Total other income	1,876.4	1,205.9	1,572.9	4,131.4	4,986.4	6,218.5
	Total income (1+2)	88,335.4	84,062.9	81,358.1	2,52,128.8	2,38,402.5	3,23,455.8
3	Expenses						
	(a) Cost of materials consumed	27,548.8	25,098.0	27,287.4	77,998.4	79,372.5	1,07,367.6
	(b) Purchase of stock-in-trade	8,926.5	8,460.5	8,238.9	25,465.0	22,509.3	28,871.1
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1,663.2)	(169.9)	(2,372.2)	(2,870.5)	(5,898.2)	(5,976.3)
	(d) Employee benefits expense	13,100.6	12,773.3	11,315.5	38,161.9	33,129.8	44,756.2
	(e) Finance costs	927.7	952.4	1,184.8	2,857.6	3,422.2	4,572.4
	(f) Foreign exchange loss (net)	-	-	498.3	-	342.5	226.5
	(g) Depreciation, amortisation and impairment expense	4,647.3	4,291.9	4,185.3	12,996.2	12,049.9	16,494.2
	(h) Other expenses	20,812.9	19,914.1	19,037.5	58,694.0	56,167.5	76,164.3
	Total expenses	74,300.6	71,320.3	69,375.5	2,13,302.6	2,01,095.5	2,72,476.0
4	Profit before share of profit/(loss) of associates and joint ventures, exceptional items and tax (1+2-3)	14,034.8	12,742.6	11,982.6	38,826.2	37,307.0	50,979.8
5	Share of profit/(loss) of associates and joint ventures, net of tax	3.7	16.6	15.9	39.5	5.0	(316.9)
6	Profit before exceptional items and tax (4+5)	14,038.5	12,759.2	11,998.5	38,865.7	37,312.0	50,662.9
7	Exceptional items (refer note 8)	653.3	-	-	653.3	-	-
8	Profit before tax (6-7)	13,385.2	12,759.2	11,998.5	38,212.4	37,312.0	50,662.9
9	Tax expense						
	Current tax	3,833.6	4,630.3	4,980.7	13,371.1	12,694.7	16,999.8
	Deferred tax	453.6	(352.4)	(1,437.9)	(980.0)	(1,190.1)	(1,172.6)
	Total tax expense	4,287.2	4,277.9	3,542.8	12,391.1	11,504.6	15,827.2
10	Profit after tax (8-9)	9,098.0	8,481.3	8,455.7	25,821.3	25,807.4	34,835.7
11	Other comprehensive Income						
	A) Items that will not be reclassified subsequently to profit or loss:						
	i) Re-measurement of defined employee benefit liability	(19.9)	(6.1)	(30.2)	(47.9)	(107.2)	(190.2)
	ii) Equity investments through other comprehensive income – net change in fair value	(10.9)	8.8	9.7	10.2	57.6	105.9
	iii) Income-tax relating to items that will not be reclassified to profit or loss	6.4	(0.7)	5.6	8.5	15.1	21.1
	B) Items that will be reclassified subsequently to profit or loss:						
	i) Exchange differences on translating the financial statements of foreign operations	2,301.7	5,408.7	(637.8)	11,775.6	1,674.1	3,099.4
	ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	Total other comprehensive income/(loss) (net of tax)	2,277.3	5,410.7	(652.7)	11,746.4	1,639.6	3,036.2
12	Total comprehensive income (net of tax) (10+11)	11,375.3	13,892.0	7,803.0	37,567.7	27,447.0	37,871.9
	Attributable to:						
	Owners of the Parent Company	11,380.1	13,895.2	7,805.4	37,581.2	27,463.7	37,895.1
	Non-controlling interest	(4.8)	(3.2)	(2.4)	(13.5)	(16.7)	(23.2)
	Out of total comprehensive income above,						
	Profit after tax attributable to:						
	Owners of the Parent Company	9,102.9	8,484.5	8,458.1	25,834.9	25,824.1	34,858.8
	Non-controlling interest	(4.9)	(3.2)	(2.4)	(13.6)	(16.7)	(23.1)
	Other comprehensive income/(loss) attributable to:						
	Owners of the Parent Company	2,277.2	5,410.7	(652.7)	11,746.3	1,639.6	3,036.3
	Non-controlling interest	0.1	-	-	0.1	-	(0.1)
13	Paid-up equity share capital (face value ₹ 1 per share)	580.8	580.8	580.8	580.8	580.8	580.8
14	Other equity						
15	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	15.67	14.61	14.56	44.48	44.25	59.81
	(b) Diluted (in ₹)	15.67	14.61	14.56	44.48	44.25	59.81



W. - - - - - Y



NOTES:

1 The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2 The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.

3 The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on February 9, 2026. The results for the quarter and nine months ended December 31, 2025 have been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2025.

4 The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".

5 During the quarter and nine months ended December 31, 2025:

(i) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics B.V., Netherlands through CuraTeQ Biologics Private Limited, India (wholly owned subsidiary) on May 28, 2025.

(ii) The Company, incorporated a step-down subsidiary, Cresedemo Pharma LLC through Aurobindo Pharma USA Inc., (wholly owned subsidiary) on June 13, 2025.

(iii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD. through Helix Healthcare B.V., The Netherlands, (wholly owned subsidiary) on September 17, 2025.

(iv) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics (Malta) Limited through CuraTeQ Biologics B.V., The Netherlands, (wholly owned subsidiary) on September 26, 2025.

(v) Pharmacin B.V (wholly owned subsidiary of Agile Pharma BV) merged with Agile Pharma BV (wholly owned subsidiary of Helix Healthcare B.V., The Netherlands) w.e.f. July 1, 2025.

(vi) Helix Healthcare B.V, The Netherlands, (wholly owned subsidiary) has transferred its 100% stake in CuraTeQ Biologics s.r.o., Czech Republic (wholly owned subsidiary) to CuraTeQ Biologics B.V, The Netherlands (wholly owned subsidiary) w.e.f. July 29, 2025.

(vii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma Chile SpA through Helix Healthcare B.V, (wholly owned subsidiary) on October 07, 2025.

(viii) The Company, incorporated a step-down subsidiary, Eugia Pharma Chile SpA through Eugia Pharma B.V, (wholly owned subsidiary) on October 07, 2025.

(ix) The Company, incorporated a step-down subsidiary, Aurobindo Pharma Philippines Inc. through Helix Healthcare B.V, (wholly owned subsidiary) on January 23, 2026.

6 During the current quarter, Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, has entered into a definitive agreement to acquire 100% of membership interest in Lannett Company LLC. The proposed transaction is subject to certain regulatory approvals. Accordingly, no financial impact has arisen in the quarter and nine months ended December 31, 2025.

7 On January 01, 2026, Auro Pharma Limited (a wholly owned subsidiary of the Company), has signed a Business transfer agreement for purchase of non-oncology prescription formulations business from M/s Khandelwal Laboratories Private Limited on a going concern basis. The agreement for the acquisition of this non-oncology prescription formulations includes transfer of Brands, Distribution network, Intellectual property, Workforce and others for a total consideration of ₹ 3,250 million, consisting of an upfront cash payment of ₹ 3,000 million, and a deferred consideration upto ₹ 250 million which is payable subject to certain conditions precedence.

8 On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability (arising out of past service cost) and increase in leave liability aggregating ₹ 653.3 million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount under "Exceptional Items" in the Consolidated Statement of Profit and Loss for the quarter and nine months ended December 31, 2025. The Group continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits.

By Order of the Board
For Aurobindo Pharma Limited


K. Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

Place: Hyderabad
Date : February 9, 2026



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **AUROBINDO PHARMA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/loss after tax and total comprehensive income/loss of its associates and joint ventures for the quarter and nine months ended December 31, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of subsidiaries, associates and joint ventures listed in Annexure I.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results includes the interim financial information of 22 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenue of ₹ 52,193.9 million and ₹ 147,341.2 million for the quarter and nine months ended December 31, 2025 respectively, total net profit after tax of ₹ 1,330.0 million and ₹ 4,475.3 million for the quarter and nine months ended December 31, 2025 respectively, total comprehensive income (net) of ₹ 1,322.1 million and ₹ 4,460.5 million for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.



**Deloitte
Haskins & Sells**

7. The unaudited consolidated financial results includes the interim financial information of 52 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of ₹ 16,729.6 million and ₹ 47,459.2 million for the quarter and nine months ended December 31, 2025 respectively, total profit after tax (net) of ₹ 119.5 million and ₹ 767.9 million for the quarter and nine months ended December 31, 2025 respectively, total comprehensive profit of ₹ 122.3 million and ₹ 770.7 million for the quarter and nine months ended December 31, 2025 respectively. The unaudited consolidated financial results also includes the Group's share of profit after tax of ₹ 3.7 million and ₹ 39.5 million for the quarter and nine months ended December 31, 2025 and total comprehensive income of ₹ 3.7 million and ₹ 39.5 million for the quarter and nine months ended December 31, 2025, as considered in the Statement, in respect of 2 associates and 3 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



C Manish Muralidhar
Partner
(Membership No. 213649)
(UDIN: 26213649ZWHYJN1774)

Place: Hyderabad
Date: February 09, 2026

Annexure I to the Independent Auditor's Report on Review of Interim Consolidated Financial Results

The interim unaudited consolidated financial results include results of the following entities:

S.No	Name of Component	Country	Relationship
1	Helix Healthcare B.V.	The Netherlands	Direct Subsidiary
2	APL Pharma Thai Limited	Thailand	Direct Subsidiary
3	Aurobindo Pharma Industria Farmaceutica Ltd	Brazil	Direct Subsidiary
4	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Direct Subsidiary
5	All Pharma (Shanghai) Trading Co Ltd	China	Direct Subsidiary
6	Aurobindo Pharma USA Inc.	USA	Direct Subsidiary
7	APL Healthcare Limited	India	Direct Subsidiary
8	Auro Peptides Limited	India	Direct Subsidiary
9	Apitoria Pharma Private Limited	India	Direct Subsidiary
10	Auroactive Pharma Private Limited	India	Direct Subsidiary
11	CuraTeQ Biologics Private Limited	India	Direct Subsidiary
12	AuroZest Private Limited	India	Direct Subsidiary
13	Aurobindo Antibiotics Private Limited	India	Direct Subsidiary
14	Eugia Pharma Specialities Limited	India	Direct Subsidiary
15	GLS Pharma Limited	India	Direct Subsidiary
16	TheraNyM Biologics Private Limited	India	Direct Subsidiary
17	Auro Pharma Limited (formerly known as Auro Trading Private Limited)	India	Direct Subsidiary
18	Aurobindo Pharma Foundation	India	Direct Subsidiary
19	Auro Vaccines Private Limited	India	Step-Down Subsidiary
20	Agile Pharma B.V.	The Netherlands	Step-Down Subsidiary
21	Milpharm Limited	United Kingdom	Step-Down Subsidiary
22	Aurobindo Pharma (Malta) Ltd	Malta	Step-Down Subsidiary
23	APL Swift Services (Malta) Ltd	Malta	Step-Down Subsidiary
24	Aurobindo Pharma (Romania) s.r.l	Romania	Step-Down Subsidiary
25	Pharmacin B.V. (Merged with Agile Pharma B.V. w.e.f July 01, 2025)	The Netherlands	Step-Down Subsidiary
26	Aurovitas Pharma Polska	Poland	Step-Down Subsidiary
27	Generis Farmaceutica S.A.	Portugal	Step-Down Subsidiary
28	Generis Phar, Unipessoal Lda	Portugal	Step-Down Subsidiary
29	Aurobindo Pharma (Italia) S.r.l	Italy	Step-Down Subsidiary
30	Arrow Generiques SAS	France	Step-Down Subsidiary
31	1980 Puren Pharma GmbH, Germany	Germany	Step-Down Subsidiary
32	Puren Pharma GmbH & Co., KG	Germany	Step-Down Subsidiary
33	Aurovitas Spain SA	Spain	Step-Down Subsidiary
34	Aurobindo Pharma B.V.	The Netherlands	Step-Down Subsidiary
35	Aurovitas Spol s.r.o	Czech Republic	Step-Down Subsidiary
36	Apotex Europe B.V.	The Netherlands	Step-Down Subsidiary
37	Aurovitas Nederland B.V	The Netherlands	Step-Down Subsidiary
38	Sameko Farma B.V.	The Netherlands	Step-Down Subsidiary
39	Leidapharm B.V.	The Netherlands	Step-Down Subsidiary
40	Marel B.V.	The Netherlands	Step-Down Subsidiary
41	Pharma Dossier B.V.	The Netherlands	Step-Down Subsidiary
42	Aurobindo NV/SA	Belgium	Step-Down Subsidiary
43	CuraTeQ Biologics s.r.o.	Czech Republic	Step-Down Subsidiary
44	Eugia Pharma B.V.	The Netherlands	Step-Down Subsidiary
45	Eugia Pharma (Malta) Limited	Malta	Step-Down Subsidiary
46	Eugia (UK) Limited	United Kingdom	Step-Down Subsidiary
47	Auro Pharma Inc.	Canada	Step-Down Subsidiary
48	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary

**Deloitte
Haskins & Sells**

S.No	Name of Component	Country	Relationship
49	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
50	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
51	Aurobindo Pharma Colombia S.A.S	Colombia	Step-Down Subsidiary
52	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
53	Aurobindo Pharma Saudi Arabia Ltd Company	Saudi Arabia	Step-Down Subsidiary
54	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary
55	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
56	Aurosalud SA De CV	Mexico	Step-Down Subsidiary
57	Auro PR Inc.	Puerto Rico	Step-Down Subsidiary
58	Eugia Pharma Inc.	Canada	Step-Down Subsidiary
59	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
60	Eugia Pharma Industria Farmaceutica Limitada	Brazil	Step-Down Subsidiary
61	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
62	Eugia Pharma Colombia S.A.S.	Colombia	Step-Down Subsidiary
63	PT Aurogen Pharma	Indonesia	Step-Down Subsidiary
64	Aurolife Pharma LLC	USA	Step-Down Subsidiary
65	Auro Health LLC	USA	Step-Down Subsidiary
66	Auro AR LLC	USA	Step-Down Subsidiary
67	Auro Vaccines LLC	USA	Step-Down Subsidiary
68	AuroLogistics LLC	USA	Step-Down Subsidiary
69	Acrotech Biopharma Inc	USA	Step-Down Subsidiary
70	Auro Science LLC	USA	Step-Down Subsidiary
71	Auro Packaging LLC	USA	Step-Down Subsidiary
72	Vespyr Brands, LLC	USA	Step-Down Subsidiary
73	Eugia Inc.	USA	Step-Down Subsidiary
74	Eugia US LLC	USA	Step-Down Subsidiary
75	Eugia US Manufacturing LLC	USA	Step-Down Subsidiary
76	Eugia Steriles Private Limited	India	Step-Down Subsidiary
77	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
78	Qule Pharma Private Limited	India	Step-Down Subsidiary
79	Eugia SEZ Private Limited	India	Step-Down Subsidiary
80	Auro Pharma LLC	Russia	Step-Down Subsidiary
81	Purple Bellflower, South Africa (w.e.f. April 30, 2024)	South Africa	Step-Down Subsidiary
82	Ace Laboratories Limited (w.e.f. June 28, 2024)	United Kingdom	Step-Down Subsidiary
83	Cresedemo Pharma LLC (w.e.f. June 13, 2025)	USA	Step-Down Subsidiary
84	Curateq Biologics B.V (w.e.f May 28, 2025)	The Netherlands	Step-Down Subsidiary
85	Aurobindo Pharma (Malaysia) SDN. BHD. (w.e.f September 17, 2025)	Malaysia	Step-Down Subsidiary
86	CuraTeQ Biologics (Malta) Limited (w.e.f September 26, 2025)	Malta	Step-Down Subsidiary
87	Aurobindo Pharma Chile SpA (w.e.f October 07, 2025)	Chile	Step-Down Subsidiary
88	Eugia Pharma Chile SpA (w.e.f October 07, 2025)	Chile	Step-Down Subsidiary
89	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
90	Raidurgam Developers Limited	India	Joint venture
91	Tergene Biotech Limited	India	Joint venture
92	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
93	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate